Yondelis (Trabectedin)

Trabectedin is a type of cancer medicine. It's a special chemical made from a sea creature. Doctors use it to treat certain types of cancer, like soft tissue sarcoma, when other treatments haven't worked. It works by stopping cancer cells from growing.

Brand names:Yondelis
Medication

What people taking Yondelis (Trabectedin) report

Every report comes from a Lived member, sent anonymously.

Have you tried Yondelis (Trabectedin) for Leiomyosarcoma?

NameHow it went

About Yondelis (Trabectedin)

What It's For

Trabectedin, sold as Yondelis, is an intravenous chemotherapy drug for two types of soft-tissue sarcoma, a cancer that starts in connective tissue such as fat or muscle. It is approved for adults with liposarcoma (which arises from fat cells) or leiomyosarcoma (which arises from smooth muscle, such as the muscle of the uterus or of blood vessel walls) when the cancer cannot be removed with surgery or has spread to other parts of the body. It is used after earlier treatment with an anthracycline, the drug family that includes doxorubicin and is usually the first chemotherapy for these cancers. In other words, it is generally a later-line option rather than a first treatment. A second US brand, Evdi, introduced in 2026, contains the same active ingredient and has the same approved use. Researchers have also tested trabectedin earlier in treatment. In one large trial in people with leiomyosarcoma who had not yet had chemotherapy, adding trabectedin to doxorubicin and then continuing trabectedin alone helped people live longer than doxorubicin by itself, at the cost of more side effects. That approach is not part of the US approval, so whether it applies is a decision for a sarcoma specialist.

How It Works

Trabectedin was first found in a sea creature called a tunicate and is now made in the laboratory. It belongs to a group of cancer drugs called alkylating agents, which attach directly to DNA. Trabectedin binds to a groove in the DNA strand and bends it. That interferes with the proteins that read and repair DNA, which disrupts how the cell divides and eventually causes it to die. Because cancer cells divide often, they are especially exposed to this damage. Healthy cells that divide quickly, such as those in the bone marrow, are affected too, which is why blood counts drop during treatment.

Dosage & Administration

Trabectedin is given in a hospital or infusion center as a slow drip into a vein lasting 24 hours, repeated every three weeks. Each three-week period is called a cycle. Treatment usually continues for as long as the cancer is controlled and side effects remain manageable. It is given through a central line, a thin tube placed in a large vein in the chest, often with a port under the skin. A central line is required because the drug badly damages tissue if it leaks out of a smaller vein. A steroid called dexamethasone is given into a vein about 30 minutes before every dose. The dose of trabectedin is based on body size and on liver function: people with moderately reduced liver function start at a lower dose. The team may delay a cycle or lower the dose if blood counts, liver tests or muscle tests are off, and once lowered, the dose is not raised again.

Side Effects

The most common side effects are nausea, tiredness, vomiting, constipation, poor appetite, diarrhea, swelling in the legs or feet, shortness of breath and headache. Anti-nausea medicine is often given, and fatigue tends to build over several cycles. Low white blood cell counts are common, usually about two weeks after a dose, and can lead to serious, sometimes fatal, infections. Call the care team right away for a fever, and also for unusual bruising or bleeding, or for new tiredness or paleness, which can mean low platelets or red blood cells. Several other serious problems are specific to this drug, and any of their signs means calling the care team right away. Liver injury can cause yellowing of the skin or eyes, pain in the upper right abdomen, severe nausea or vomiting, or confusion. Muscle breakdown, which can damage the kidneys, can cause severe muscle pain or weakness or reddish-brown urine. Weakening of the heart can cause new chest pain, shortness of breath, leg swelling or a racing or pounding heartbeat. A rare leak of fluid from blood vessels can cause sudden widespread swelling, sometimes with dizziness from low blood pressure. Damage to the tissue around the line or port shows up as redness, swelling, pain or leakage at the site, and can appear more than a week after an infusion. Allergic reactions are uncommon. Trouble breathing, wheezing, chest tightness, swelling of the lips or severe dizziness during or after an infusion needs immediate medical attention.

Interactions & Warnings

Trabectedin is broken down in the liver by an enzyme called CYP3A, so medicines that strongly affect that enzyme change how much drug stays in the body. Strong inhibitors (medicines that block CYP3A) raise trabectedin levels and side effects. Examples include the antifungals ketoconazole, itraconazole, posaconazole and voriconazole, the antibiotic clarithromycin, and some HIV medicines such as ritonavir. Strong inducers (medicines that speed up CYP3A) lower its levels and may make it less effective, including the tuberculosis antibiotic rifampin, the seizure medicine phenobarbital and the herbal supplement St. John's wort. If a short course of a strong inhibitor cannot be avoided, the team can time it between infusions. Check any new prescription or supplement with the oncology team or pharmacist. Trabectedin is not given to people with severe liver impairment or a past severe allergic reaction to it. Heart problems are more likely in people over 65, people with existing heart disease or reduced heart pumping, and people who have already received high total doses of doxorubicin or another anthracycline. Trabectedin can harm a developing baby. People who could become pregnant should use effective contraception during treatment and for at least 8 months after the last dose, and men with partners who could become pregnant for at least 5 months after. Breastfeeding should stop during treatment and for 3 months after the last dose. Contact the team promptly about a possible pregnancy.

What to Expect

Before each dose, blood tests check white cells, platelets, liver function and creatine phosphokinase (CPK), a muscle enzyme that rises when muscle is damaged. Heart pumping is measured with an echocardiogram (an ultrasound of the heart) or a MUGA (multigated acquisition) scan, which uses a small amount of radioactive tracer to measure how well the heart pumps, before starting and every two to three months during treatment. Delays and dose reductions are common and are a normal way of keeping treatment safe: in the main trial, about half of people had a dose held and four in ten had the dose lowered, most often because of blood counts or liver tests. Liver test rises usually appear in the first month and most settle within a few weeks. The goal for most people is to slow the cancer rather than cure it. Scans every few cycles show whether the tumor is stable, shrinking or growing. In the trial that led to approval, trabectedin kept the cancer from growing for longer than another chemotherapy, dacarbazine (half of people went longer than about 4 months before the cancer grew, compared with 1.5 months), but people did not live longer overall, and only a small share had their tumors shrink noticeably. In that trial, about three in ten people stayed on treatment for more than six months. Others stop because the cancer grows or side effects become too much, and the team then discusses other options, including clinical trials.

Questions to Ask Your Doctor

  1. 1.Why is trabectedin a good next step for my type of sarcoma compared with other options or a clinical trial?
  2. 2.What would count as success for me, and how often will scans check whether it is working?
  3. 3.Will I need a new central line or port, and where and how will the 24-hour infusion be given?
  4. 4.What should I do if I get a fever or other warning signs at night or on a weekend, and who do I call?
  5. 5.Do any of my current medicines or supplements interact with trabectedin, and what contraception plan makes sense for me?

Last reviewed • Oct 2026

Educational content, not medical advice.